Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors | New

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced today Today Neha Krishnamohan was appointed to the Arcutis Board of Directors and a member of the Audit Committee. Following the appointment, the Board will be composed of 10 directors.

“We are absolutely delighted to welcome Neha to the Arcutis Board of Directors,” said Frank Watanabe, President and CEO of Arcutis. “Neha brings incredible business, finance and investment experience, and has a deep understanding of our business, having worked on our initial public offering in a previous role. She will be a wonderful addition to our Board of Directors and will support the next stage of growth for Arcutis. I am incredibly proud of the caliber and diversity of our entire Board of Directors, and look forward to working with Neha again as we bring meaningful innovation to medical dermatology.

“I am honored to join the Arcutis Board of Directors at this pivotal time following the recent commercialization of ZORYVE™ Cream (roflumilast) for plaque psoriasis, an important new treatment option for adults and teenagers,” said Neha Krishnamohan. “Since working on the Arcutis IPO, I have been impressed not only by the company’s strong dermatology development pipeline and track record of successful execution, but also by the commitment of leadership and the entire organization to addressing the unmet needs of people with immune-mediated skin diseases.”

Ms. Krishnamohan is currently the Chief Financial Officer and Executive Vice President of Corporate Development at Kinnate Biopharma, with over 12 years of experience in investment banking and healthcare finance. Previously, Ms. Krishnamohan was Vice President of the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking division of Goldman Sachs. At Goldman Sachs, she established herself as a senior executive in the Healthcare Coverage Group, working with various biopharmaceutical boards and management teams on a wide range of strategic financial matters, executing financings as well as merger and acquisition transactions. It should be noted that she was one of the lead bankers in the highly successful Arcutis 2020 IPO. medical technology and tools/diagnostics. Ms. Krishnamohan holds a Bachelor of Science degree with a double major in biomedical engineering and economics from Duke University.


ZORYVE (roflumilast) Cream 0.3% is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.


The use of ZORYVE is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C).

Most common adverse reactions (≥1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see complete prescribing information.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to meet the urgent needs of people living with immune-mediated dermatological diseases and conditions. Committed to solving patients’ most persistent dermatology challenges, Arcutis leverages our unique dermatology development platform combined with our dermatology expertise to develop differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a strong pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, including scalp psoriasis, atopic dermatitis and seborrheic dermatitis. For more information, visit or follow Arcutis on LinkedIn, Facebook and Twitter.

Forward-looking statements

Arcutis cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the potential of ZORYVE to simplify disease management for the treatment of plaque psoriasis; the potential for real-world results of roflumilast cream, as well as the commercial launch of ZORYVE in plaque psoriasis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from the information expressed or implied by these forward-looking statements. The risks and uncertainties that could cause our actual results to differ include the risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Factors” section. of Risk” of our Form 10-K filed with the United States. Securities and Exchange Commission (SEC) on February 22, 2022, as amended, and any subsequent filings with the SEC. You should not place undue reliance on the forward-looking statements contained in this press release. We assume no obligation to revise or update the information contained herein to reflect future events or circumstances, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.



Amanda Sheldon, Corporate Communications Manager

(805) 418-5006

[email protected]


Eric McIntyre, Head of Investor Relations

(805) 418-5006

[email protected]

A photo accompanying this announcement is available at

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.